Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

By | April 3, 2022
Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental “gene silencing” therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.